PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer
Uro-Oncology
Related content
COMMENTED
Uro-Oncology
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Freedland SJ, Mulhall JP, Gleave M, Giorgi U, Saad F, Rannikko A, Ivanova JI, Nasr AF, Reisman AL, Ganguli A, Kral P, Turnbull J, Shore N
doi: 10.1016/j.eururo.2025.02.006
Uro-Oncology
Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial
J Urol
Bahler CD, Tachibana I, Tann M, Collins K, Swensson JK, Green MA, Mathias CJ, Tong Y, Yong C, Boris RS, Brocken E, Hutchins GD, Sims JB, Hill DV, Smith N, Ferari C, Love H, Koch MO
doi: 10.1097/JU.0000000000004032
Benign Prostatic Hyperplasia (BPH)
Do Prostate Imaging-Reporting and Data System (PIRADS) lesions predict holmium laser enucleation of prostate outcomes?
Prostate
Tsai K, Xu P, Guo J, Dean N, Khondakar N, Michael J, Neill C, Krambeck A
doi: 10.1002/pros.24771
Uro-Oncology
Association of Baseline MRI PI-RADS Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC)
J Urol
Nandalur KR, Shen C, Zhao L, Al-Katib S, Lee J, Seifman B, Ye H, Ginsburg K, Quinn T, Nandalur S, George A, Gangwish D, Dhaliwal A, Erwin C, Young A, Albeer A, Hafron J
doi: 10.1097/JU.0000000000004117
Uro-Oncology
Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies
Prostate Cancer Prostatic Dis
Falagario UG, Pellegrino F, Fanelli A, Guzzi F, Bartoletti R, Cash H, Pavlovich C, Emberton M, Carrieri G, Giannarini G
doi: 10.1038/s41391-024-00827-x
Benign Prostatic Hyperplasia (BPH)
Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
Prostate
Jirásko M, Viták R, Pecen L, Pinkeová A, Tkáč J, Bertók T, Bergman N, Kučera R
doi: 10.1002/pros.24801
Uro-Oncology
The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study
Prostate
Massanova M, Barone B, Caputo VF, Napolitano L, Ponsiglione A, Del Giudice F, Ferro M, Lucarelli G, Lasorsa F, Busetto GM, Robertson S, Trama F, Imbimbo C, Crocetto F
doi: 10.1002/pros.24761
Uro-Oncology
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Eur Urol
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR
doi: 10.1016/j.eururo.2024.03.036
Uro-Oncology
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Prostate Cancer Prostatic Dis
George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, Ivanova J, Thompson B, Emir B, Hong A, Freedland SJ
doi: 10.1038/s41391-024-00816-0